Akorn, Inc. (AKRX)
(Delayed Data from NSDQ)
$2.85 USD
+0.14 (5.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.86 (%) 5:22 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
NA Value NA Growth NA Momentum NA VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
NA
View All Zacks #1 Ranked Stocks
Zacks News
Akorn (AKRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Akorn's (AKRX) fourth-quarter 2019 results are likely to reflect a decline in sales volume due to stiffening competition.
AMAGPositive Net Change AKRXPositive Net Change SAGEPositive Net Change VCELPositive Net Change
pharmaceuticals
Akorn Enters Oversold Territory
by Zacks Equity Research
Akorn, Inc. (AKRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
AKRXPositive Net Change
pharmaceuticals
Akorn (AKRX) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Akorn (AKRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
AKRXPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Generic Drugmakers Gain as Price-Fixing Probe Nears an End
by Indrajit Bandyopadhyay
Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.
TEVANegative Net Change AKRXPositive Net Change ZYNEPositive Net Change BHCPositive Net Change
pharmaceuticals
Generic Drugs Industry Turns the Corner on Price Stabilization
by Indrajit Bandyopadhyay
Stabilizing prices of generic drugs are leading to recovery in the industry. New launches are also a boost. However, competition remains stiff.
ZYNEPositive Net Change BHCPositive Net Change AKRXPositive Net Change
pharmaceuticals
The Zacks Analyst Blog Highlights: Forterra, Barrett Business, Chuy's, Akorn and Quanex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Forterra, Barrett Business, Chuy's, Akorn and Quanex.
NXNegative Net Change FRTANegative Net Change AKRXPositive Net Change CHUYPositive Net Change BBSINegative Net Change
business-services construction
5 Small-Cap Stocks Outpacing the Broader Market in 2019
by Nalak Das
Despite the slow pace of movement of small-cap stock prices, a few stocks within this stable have skyrocketed ahead of the large-cap-centric indexes this year.
NXNegative Net Change FRTANegative Net Change AKRXPositive Net Change CHUYPositive Net Change BBSINegative Net Change
business-services construction pharmaceuticals retail
New Strong Buy Stocks for November 7th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
OMIPositive Net Change LADPositive Net Change CBZNegative Net Change AKRXPositive Net Change ACIAPositive Net Change
auto-tires-trucks business-services communications medical
Akorn (AKRX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Akorn (AKRX) delivered earnings and revenue surprises of 150.00% and 0.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
AKRXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Will Akorn (AKRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Akorn (AKRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AKRXPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
All You Need to Know About Akorn (AKRX) Rating Upgrade to Buy
by Zacks Equity Research
Akorn (AKRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AKRXPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Akorn (AKRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akorn (AKRX) delivered earnings and revenue surprises of 66.67% and 3.27%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
AKRXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Analysts Estimate Akorn (AKRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Akorn (AKRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AKRXPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Akorn (AKRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akorn (AKRX) delivered earnings and revenue surprises of 28.57% and 8.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
AKRXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Options Traders Expect Huge Moves in Akorn (AKRX) Stock
by Zacks Equity Research
Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.
AKRXPositive Net Change
medical
Options Traders Expect Huge Moves in Akorn (AKRX) Stock
by Zacks Equity Research
Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.
AKRXPositive Net Change
medical
Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility
by Zacks Equity Research
Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.
RDYNegative Net Change MYLPositive Net Change MNKPositive Net Change AKRXPositive Net Change
pharmaceuticals
Do Options Traders Know Something About Akorn (AKRX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.
AKRXPositive Net Change
medical
Is Akorn (AKRX) Stock a Suitable Pick for Value Investors?
by Zacks Equity Research
Let's see if Akorn, Inc. (AKRX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
AKRXPositive Net Change
undervalued-stocks value-stocks
Implied Volatility Surging for Akorn (AKRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.
AKRXPositive Net Change
medical
Is Akorn (AKRX) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if Akorn, Inc. (AKRX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
AKRXPositive Net Change
AKRX vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AKRX vs. AMPH: Which Stock Is the Better Value Option?
AKRXPositive Net Change AMPHNegative Net Change
Bausch (BHC) Looks Good: Stock Adds 13.9% in Session
by Zacks Equity Research
Bausch (BHC) shares rose nearly 14% in the last trading session, amid huge volumes.
AKRXPositive Net Change BHCPositive Net Change
Akorn Enters Oversold Territory
by Zacks Equity Research
Akorn has been on a bit of a cold streak lately.
AKRXPositive Net Change
AKRX vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AKRX vs. AMPH: Which Stock Is the Better Value Option?
AKRXPositive Net Change AMPHNegative Net Change